Literature DB >> 19519422

Application of high hydrostatic pressure to dissociate aggregates and refold proteins.

Matthew B Seefeldt1, Mary S Rosendahl, Jeffrey L Cleland, Lyndal K Hesterberg.   

Abstract

Non-denaturing pressures of around 2000 bar are effective for eliminating and refolding protein aggregates and may be applicable in various phases of protein manufacturing to decrease aggregate levels in products and improve process yields. Lower aggregate levels can result in reduced immunogenicity of proteins and enable the correct refolding of proteins that might not be recovered with traditional techniques. High pressure treatment can also be used to conduct selective PEGylation and protease cleavage reactions while minimizing protein aggregation. High pressure processes have been used in the food industry for over 50 years and large scale (300 L) systems are commercially available, enabling production of proteins on the kilogram scale. This review summarizes the utility of high pressure refolding to remove and refold protein aggregates, enhance therapeutic proteins, and facilitate manufacturing improvements at industrial scales.

Mesh:

Substances:

Year:  2009        PMID: 19519422     DOI: 10.2174/138920109788488914

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  12 in total

1.  Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions.

Authors:  Austin L Daniels; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2018-02-01       Impact factor: 3.534

Review 2.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

3.  Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS.

Authors:  Björn Boll; Emilien Folzer; Christof Finkler; Jörg Huwyler; Hanns-Christian Mahler; Roland Schmidt; Atanas V Koulov
Journal:  Pharm Res       Date:  2015-07-21       Impact factor: 4.200

4.  In vivo disassembly and reassembly of protein aggregates in Escherichia coli.

Authors:  Sander K Govers; Philip Dutré; Abram Aertsen
Journal:  J Bacteriol       Date:  2014-03-14       Impact factor: 3.490

Review 5.  Factors affecting the physical stability (aggregation) of peptide therapeutics.

Authors:  Karolina L Zapadka; Frederik J Becher; A L Gomes Dos Santos; Sophie E Jackson
Journal:  Interface Focus       Date:  2017-10-20       Impact factor: 3.906

6.  Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicity.

Authors:  Riccardo Torosantucci; Victor S Sharov; Miranda van Beers; Vera Brinks; Christian Schöneich; Wim Jiskoot
Journal:  Mol Pharm       Date:  2013-05-02       Impact factor: 4.939

7.  Expression, high-pressure refolding, purification, crystallization and preliminary X-ray analysis of a novel single-strand-specific 3'-5' exonuclease PhoExo I from Pyrococcus horikoshii OT3.

Authors:  Ken-ichi Miyazono; Kanae Tsutsumi; Yoshizumi Ishino; Masaru Tanokura
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-07-23       Impact factor: 1.056

Review 8.  Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.

Authors:  Wim Jiskoot; Grzegorz Kijanka; Theodore W Randolph; John F Carpenter; Atanas V Koulov; Hanns-Christian Mahler; Marisa K Joubert; Vibha Jawa; Linda O Narhi
Journal:  J Pharm Sci       Date:  2016-04-01       Impact factor: 3.534

9.  Under pressure that splits a family in two. The case of lipocalin family.

Authors:  Stephane Marchal; Anna Marabotti; Maria Staiano; Antonio Varriale; Thomas Domaschke; Reinhard Lange; Sabato D'Auria
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

10.  Inactivation of caliciviruses.

Authors:  Raymond Nims; Mark Plavsic
Journal:  Pharmaceuticals (Basel)       Date:  2013-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.